Clinical and prognostic significance of PMN in children with glomerular C1q deposition

CURRENT STATUS: POSTED

Ren Wang
Nanjing Medical University

Meiqiu Wang
Southern Medical University

Zhengkun Xia
Department of Pediatrics, Jinling Hospital, The First School of Clinical Medicine, Southern Medical University

njxzk@126.com Corresponding Author
ORCID: https://orcid.org/0000-0003-3281-8766

Chunlin Gao
Southern Medical University

shuangmu34@163.com Corresponding Author

Zhuo Shi
Jinling Hospital

Xiang Fang
Southern Medical University

Heyan Wu
Southern Medical University

Yingchao Peng
Southern Medical University

10.21203/rs.3.rs-23486/v1

SUBJECT AREAS
Urology & Nephrology

KEYWORDS
Primary membranous nephropathy in children; C1q deposition; prognosis; clinical
Abstract

Background
Currently, studies to data in MN are consistent with complement activation has an essential role in mediating renal injury, and the LP is considered to be the principal pathway in PMN. CP activation initiated by C1q which deposits are suggestive of SMN. However, C1q deposition together with IgG and C3 granular deposit is found in many cases of PMN. Currently, the clinical and prognostic significance of C1q deposition in PMN is unclear. Therefore, we conduct this single-center research to explore the clinical and prognostic significance of C1q deposition in children with PMN.

Method:
73 patients with C1q deposition were enrolled in this study. According to the “Case-control matching principle”, 73 patients without C1q deposition during the same period of the renal biopsy were selected as a control group. The clinical and pathological characteristics, treatment response, and long-term renal prognosis were compared between patients with and without C1q deposition.

Result
A total of 146 pediatric patients with PMN included with 86 men (58.9%) and 60 women (41.1%). The median age at onset was 15.0 (14.0—16.0) years. During an average follow-up of 52.4 ± 35.6 months, 8 patients (5.5%) progressed ESKD, 12 (8.2%) patients developed ESRD or renal dysfunction. The frequency of glomerular C4 deposits in the C1q deposits group was significantly higher than no C1q deposits group (34.2% vs 5.5%, p = 0.000). There were no other distinct differences in clinical and pathological characteristics between the two groups. Glomerular IgG subclasses were available in 79 patients, there was no difference in the glomerular IgG subclass distribution between the two groups ($p_{\text{IgG1}}=0.468, p_{\text{IgG2}}=1.000, p_{\text{IgG3}}=0.988, p_{\text{IgG4}}=0.216$). The Kaplan-Meier survival analysis found that there was no difference in the renal survival of ESRD ($p = 0.415$) and a combined event of ESRD and/or renal dysfunction ($p = 0.214$) between the two groups. The logistic regression analysis ($p = 0.553$) and Cox regression analysis ($p = 0.618$) revealed that C1q deposition failed to associate with renal dysfunction.

Conclusion
The CP does occur in some patients of PMN. However, it may be unrelated to the progression of the
disease.

**Background**

Primary membranous nephropathy (PMN) is now considered an autoimmune-mediated glomerular disease characterized by subepithelial glomerular IgG and complement. The discovery in 2009 of podocyte antigens to which circulating autoantibodies bought about a great advance in the basic and clinical research, antibodies against phospholipase A2 receptor (PLA2R) are present in 50 ~ 80% of patients with PMN[1]. However, the pathogenesis of PLA2R-associated MN is obscure. Heymann models of PMN in rats revealed that subepithelial deposits of IgG and C3 resulted from in situ immune deposit formation involving a rat podocyte antigen, and the proteinuria was mediated mainly by complement through the C5b which is a membrane attack complex[2]. Currently, whether complement activation is pathogenic in human PMN or which activation pathway might be involved remain an enigma[3]. IgG4 is the dominant subclass of IgG in PMN, it fails to bind complement and is incapable of activating the classical pathway (CP), studies to data in PMN are consistent with complement is activated though the lectin pathway (LP), and the role of the classical and alternative pathways (AP) has not been completely excluded[4–6]. The complement is intensively activated by IgG1 and IgG3 through the CP in secondary membranous nephropathy (SMN)[7, 8].

Classical pathway activation initiated by C1q which deposits are suggestive of SMN[9]. However, C1q deposition together with IgG and C3 granular deposit is found in many cases of PMN. Currently, the clinical and prognostic significance of C1q deposition in PMN is unclear. In addition, there is a paucity of studies about C1q deposition in children with PMN. Therefore, we conduct this single-center research to define the clinical and prognostic significance of C1q deposition in children with PMN by comparing various clinical and pathological characteristics, treatment response, and long-term renal prognosis in patients with and without C1q deposition.

**Methods**

1. **Participants**

All the participants in this study were recruited at Nanjing Jinling Hospital from 2005.07 to 2013.09. The inclusion criteria were: □ PMN was histologically proven by kidney biopsy; □ age ≤18 years; □
informed consent was obtained before study commencement. The exclusion criteria were as follows: patients with secondary causes of MN, including hepatitis B, autoimmune diseases, malignancies, medications, and heavy metal poisoning; renal pathology presented with “full house” pattern by immunofluorescence, HBc and HBs antigens deposit in glomeruli; Patients with follow-up less than 12 months in addition to the patient who progressed to end-stage renal disease (ESRD) or related death within 12 months. 73 patients with C1q deposition were enrolled in this study. According to the “Case-control matching principle”, 73 patients without C1q deposition during the same period of the renal biopsy were selected as a control group. Eventually, there are altogether 146 pediatric patients with PMN in this study.

2. Methods

We classified all enrolled patients into 2 groups according to whether C1q deposits in glomeruli. The patient’s general characteristics, clinical and pathological data at biopsy were collected by the reviewing of medical records. Comparing clinical and pathological characteristics between the patients with and without C1q deposition. The patient’s treatment modalities, proteinuria, serum creatinine or eGFR were collected by outpatient and telephone during the follow-up. Comparing treatment responses and long-term renal prognosis in patients with and without glomerular C1q deposits. The baseline was at renal biopsy and all follow-up dates were updated to June 2019.

The primary endpoint was ESRD which defined as eGFR ≤ 15ml/min/1.73m² or the requirement of maintenance dialysis or transplantation. The secondary endpoint was renal dysfunction, defined as eGFR decline by 30% from the time of renal biopsy and to < 60 ml/min/1.73m². Hypertension was diagnosed according to the criterion recommended by the updating blood pressure references for Chinese children aged 3-17 years established by Jie Mi et al (All enrolled patients were aged 3-17 years). Children less than 16-year-old used Schwartz formula to estimate eGFR, then, eGFR was computed adopting the chronic kidney disease epidemiology collaboration formula (CKD-EPI) among children more than 16 years old. The disease stages were based on Ehrenreich and Churg’s classification criteria by electron microscopy. Case-control matching principle was considered that the
sex, age, and stage of chronic kidney disease of the case group are matched with the control group. Complete remission (CR) was defined as blood biochemical and urinalysis were completely normal. Partial remission (PR) was defined as proteinuria was qualitatively positive≤ 2+ and/or edema disappeared, a serum albumin level of more than 25g/L. We defined no remission (NR) as proteinuria ≥ 3+. Relapse was defined as proteinuria of at least 50mg/kg per 24 hours, or urine protein to creatinine ratio (mg/mg) ≥ 2.0, or proteinuria from negative to 3+ ~ 4+ for 3 consecutive days, except for infections. **Statistical Analysis** The SPSS software (version19.0, Chicago, IL, USA) was taken for the statistical analysis. Normally distributed variables were presented as the mean±SD and compared using Student’s t-test. Continuous variables with skewed distributions were expressed as medians and ranges, the nonparametric test was used for comparison. Categorical variables were presented as percentages and compared using the chi-square test. The Kaplan-Meier method was used to calculate renal survival rates and comparisons were by the log-rank test. Risk factors for treatment responses were analyzed using logistic regression analysis. The COX proportional hazard regression model was used to evaluate the relationship between the parameters at baseline and renal survival. All P values were two sides, value < 0.05 was considered statistically significant. **Results** 1. Clinical data and renal outcomes of children with PMN. A total of 146 pediatric patients with PMN included with 86 men (58.9%) and 60 women (41.1%). The median age at onset was 15.0(14.0—16.0) years. 48 (32.9%) patients presented with hypertension, nephrotic syndrome occurred in 67.8% of patients. 116 patients (79.5%) received immunosuppressive agents. 126 patients (86.3%) achieved remission, including 83 patients (56.8%) who achieved CR in 8.5±6.4—13.0±months and 43±29.5% patients who achieved PR in 4.5±3.0—6.0±months. Relapse occurred in 33 patients (22.6%). During an average follow-up of 52.4±35.6 months, 8 patients (5.5%) progressed ESKD, 12 (8.2%) patients developed ESRD or renal dysfunction.
2. Clinical data and renal outcomes of PMN in children with C1q deposition (*Table 1*).

The clinical and pathological features, treatment responses, and renal prognosis of patients with and without C1q deposition were listed in **Table 1**.

73 patients C1q deposition were enrolled in our center, including 43 males (58.9%) and 30 females (41.1%) with a male predominance, the median age at onset was 15.0 (14.0–16.0) years old. 22 patients (30.1%) presented with hypertension and 46 patients (63.0%) manifested as nephrotic syndrome, there were no statistical differences between the two groups \( (p_{\text{hypertension}}=0.484, p_{\text{nephrotic syndrome}}=0.215) \). The frequency of glomerular C4 deposits in the C1q deposits group was significantly higher than no C1q deposits group (34.2% vs 5.5%, \( p=0.000 \)). There were no other distinct differences in baseline characteristics and renal outcomes between the two groups, including proteinuria, serum creatinine, eGFR, the level of serum immunoglobulin and complement, pathological stage, treatment responses, and renal prognosis.

3. The glomerular IgG subclass of PMN in children with C1q deposition (*Table 2*).

Glomerular IgG subclasses were available in 79 patients. There were 37 patients with C1q deposition, 36 (97.3%) with IgG1 deposits, 33 (89.2%) with IgG2 deposits, 30 (81.1%) with IgG3 deposits, 35 (94.6%) with IgG4 deposits. There was no difference in the glomerular IgG distribution between the two groups \( (p_{\text{IgG1}}=0.468, p_{\text{IgG2}}=1.000, p_{\text{IgG3}}=0.988, p_{\text{IgG4}}=0.216) \).

4. The long-term renal outcomes and related risk factors of PMN in children with C1q deposition.

During an average follow-up of 53.8±35.7 months among the patients with C1q deposition, 3 patients progressed the primary endpoint, the cumulative renal survival rates of the primary endpoint at 5 and 10 years after biopsy were 98.2% and 78.6%, respectively. 4 patients developed the secondary endpoint, the cumulative renal survival rates of secondary endpoint at 5 and 10 years after biopsy were 98.2% and 69.8%, respectively.

The Kaplan-Meier survival analysis was performed to compare the long-term renal survival between the two groups. The results revealed that there was no difference in the renal survival of the primary endpoint \( (p=0.415) \) (**Figure 1**) and secondary endpoint \( (p=0.214) \) (**Figure 2**) between the two
groups.

Logistic regression analysis was used to explore the risk factors for NR (Table 3). The results showed that proteinuria >50mg/kg/day was the only risk factor of NR (OR=1.615, 95% CI=0.609—4.281 p=0.035). However, C1q deposition could not predict NR (p=0.553).

The Cox regression analysis was used to evaluate the relationship between the parameters at baseline and renal dysfunction (Table 4). NR was significantly correlated with renal dysfunction in the univariate analysis (HR=8.866, 95% CI = 2.347—33.495 p=0.001). Parameters with P values lower than 0.1 in the univariate were enrolled in the multivariate COX regression analysis. Multivariate Cox regression analysis further confirmed that NR was an independent risk factor of renal dysfunction (HR=9.064, 95% CI = 2.400—34.233, p=0.001 ). C1q deposition could not predict renal dysfunction (p=0.618).

Discussion
This single-center study was conducted to explore the clinical and pathological characteristics, treatment responses, and renal outcomes of PMN in children with C1q deposition. 73 pediatric patients with C1q deposition were enrolled, 73 patients without C1q deposition were selected according to the Case-control matching principle. Therefore, there was no comparison in age and gender between the two groups. Despite the reported rates were various in children, hypertension seemed to be uncommon in children according to previous reports. There was no significant difference in hypertension between the two groups, but over a third of the patients present with hypertension in both groups. Nephrotic syndrome was the most prominent clinical manifestation in both groups, with no difference in the prevalence, all of which were slightly higher than that in adults with PMN (60%)[3]. The laboratory data consisted of 24-hour urinary protein, serum creatinine, serum albumin, serum IgA, serum IgG, serum IgM, serum C3 of patients in the C1q deposits group were comparable to those in the no C1q deposits group. However, a previous study reported that the level of serum IgG in no C1q deposits group was higher than the C1q deposits group (p=0.008)[10]. Renal pathological parameters included pathological stage, the frequency of glomerular IgA, IgG, IgM deposits were also similar between the two groups. Whereas a retrospective study in adult PMN
pointed out that there were less MN stage I patients in the C1q deposits group than no C1q deposits group, and more stage III patients (p<0.001). The positive rates of glomerular IgA (p<0.001), IgM (p=0.011), and C3 (p=0.004) deposits in the C1q deposits group were significantly higher than no C1q deposits group[10]. C4 was activated through the CP or the LP, C4d is a cleavage product of C4 activation. C4d deposition together with C1q and immunoglobulin granular deposit that suggests activation of the classical pathway, C4d with or without immunoglobulin deposition, as well as without C1q deposition, suggested activation of the LP[11,12]. The positive rate of C4 deposits in the C1q deposits group was significantly higher than no C1q deposits group in this cohort. The finding suggests that the CP of complement activation occurs in the C1q deposits group. There was no difference in treatment responses and long-term renal outcomes between the two groups, which consistent with a previous study[10]. The rate of self-recovery in children with PMN is high, the consensus has been reached that immunosuppression should be treated in the presence of nephrotic proteinuria and hypoalbuminemia, proteinuria increased by more than 50% during follow-up, serum creatinine increased by more than 30% during follow-up for 6~12 months, thrombosis and other severe adverse events.[1,13,14]. However, more than 75 percent of patients were on immunosuppressive agents in both groups. It may be associated with the severity of the patients in our cohort.

C1q deposits generally suggests SMN[2,15], which is a rare finding in PMN (<20%)[16]. None of PMN patients with C1q deposition progressed SMN during follow-up. Therefore, except renal pathology presented with a “full house” pattern by immunofluorescent staining, C1q deposits may not play a pathogenic role in SMN[17,18].

PMN is a rare pathological finding in pediatric patients, occupies 1.5±9% of biopsies during the corresponding period[19]. There is a rarity of data about the prognosis in children with PMN due to small samples with a fairly short follow-up period. Several studies reported that 21±29% of pediatric PMN presented with renal dysfunction at the last follow-up[20]. We performed the Kaplan-Meier survival analysis to compare the long-term renal survival between the patients with and without C1q deposition. The results found that the C1q deposits group showed comparable renal survival compared
to no C1q deposits group. According to previous studies, the established risk factors of PMN in adults include age (≥50 years old), gender (male), decreased eGFR on presentation, persistent heavy proteinuria, increased excretion of urinary C3dg, urinary C5b-9 and β2 microglobulin[3]. Whereas considerably fewer studies have analyzed the association between glomerular C1q deposits and renal outcome. The logistic regression analysis was used to explore the risk factors for NR in this research, and the Cox regression analysis was used to evaluate the relationship between the parameters at baseline and renal survival. As a result, C1q deposition failed to associate with disease progression, which was confirmed by previous studies.

The clinical and pathological characteristics, treatment responses and renal outcomes of patients with C1q deposition were similar to the patients without C1q deposition. These findings show that the CP of complement activation may occur in some patients with PMN, while it has no direct impact on renal injury and may not play an essential role in the pathogenesis of the disease. Thus, the treatment of PMN should target to common pathway rather than any one individual pathway.

**Conclusion**

The CP does occur in some patients of PMN. However, it may be unrelated to the progression of the disease.

**Abbreviations**

- Primary membranous nephropathy: PMN
- Phospholipase A2 receptor: PLA2R
- Classical pathway: CP
- Lectin pathway: LP
- Alternative pathways: AP
- Secondary membranous nephropathy: SMN
- End-stage renal disease: ESRD
- Chronic kidney disease epidemiology collaboration formula: CKD-EPI
- Complete remission: CR
- Partial remission: PR
No remission: NR

Systemic lupus erythematosus: SLE

Declarations

**Ethics approval and consent to participate** All data were obtained via electronic medical records and a database review and were de-identified (the patient’s name was replaced with an identification code, and the patient’s private information was deleted before the analysis) to protect patient privacy. This study was approved by the Institutional Ethics Committee of Nanjing Jinling Hospital;

**Consent to publication:** Not applicable;

**Availability of data and materials:** Not applicable;

**Competing interests** The authors declare that they have no competing interests;

**Funding** This work was supported by the project of Clinical Advanced Techniques, Primary Research & Development Plan of Jiangsu Province (BE2017719), and the Pediatric Medical Innovation Team of Jiangsu Province (CXTDA2017022); The funder serve for the author's service fee and the publication fee of the manuscript. So the funder play a very important role in funding the publication of the article.

**Authors' contributions:** RW, MQ W both are principal co-investigators, contributed equally to study design, data analysis and draft the manuscript. ZK X, CL G, and ZS are co-investigators who reviewed the data for this study and participated in discussions around the observed outcomes. XF, HY W and YC P are independent members who collected the data. All authors were involved in the writing of the manuscript and the decision to submit the manuscript for publication.

**Acknowledgements** The authors acknowledge support from the Clinical Advanced Techniques, Primary Research & Development Plan of Jiangsu Province (BE2017719) and the Pediatric Medical Innovation Team of Jiangsu Province (CXTDA2017022).

**References**

1. Floege J, Barbour SJ, Cattran DC, Hogan JJ, Nachman PH, Tang S, et al. Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. KIDNEY INT.
2. Sinico RA, Mezzina N, Trezzi B, Ghiggeri GM, Radice A. Immunology of membranous nephropathy: from animal models to humans. CLIN EXP IMMUNOL. 2016;183(2):157-65.

3. Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol. 2017;12(6):983-97.

4. Reddy YN, Siedlecki AM, Francis JM. Breaking down the complement system: a review and update on novel therapies. Curr Opin Nephrol Hypertens. 2017;26(2):123-8.

5. Takano T, Elimam H, Cybulsky AV. Complement-mediated cellular injury. SEMIN NEPHROL. 2013;33(6):586-601.

6. Ma H, Sandor DG, Beck LJ. The role of complement in membranous nephropathy. SEMIN NEPHROL. 2013;33(6):531-42.

7. Huang CC, Lehman A, Albawardi A, Satoskar A, Brodsky S, Nadasdy G, et al. IgG subclass staining in renal biopsies with membranous glomerulonephritis indicates subclass switch during disease progression. Mod Pathol. 2013;26(6):799-805.

8. Debiec H, Ronco P. Immunopathogenesis of membranous nephropathy: an update. SEMIN IMMUNOPATHOL. 2014;36(4):381-97.

9. Larsen CP, Messias NC, Silva FG, Messias E, Walker PD. Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies. Mod Pathol. 2013;26(5):709-15.

10. Zhang MF, Cui Z, Zhang YM, Qu Z, Wang X, Wang F, et al. Clinical and prognostic significance of glomerular C1q deposits in primary MN. CLIN CHIM ACTA. 2018;485:152-7.

11. Sethi S, Quint PS, O'Seaghdha CM, Fervenza FC, Bijol V, Dorman A, et al. C4 Glomerulopathy: A Disease Entity Associated With C4d Deposition. AM J KIDNEY DIS.
12. Garam N, Prohaszka Z, Szilagyi A, Aigner C, Schmidt A, Gaggl M, et al. C4 nephritic factor in patients with immune-complex-mediated membranoproliferative glomerulonephritis and C3-glomerulopathy. ORPHANET J RARE DIS. 2019;14(1):247.

13. Ruggenenti P, Fervenza FC, Remuzzi G. Treatment of membranous nephropathy: time for a paradigm shift. NAT REV NEPHROL. 2017;13(9):563–79.

14. Kumar V, Varma AK, Nada R, Ghosh R, Suri D, Gupta A, et al. Primary membranous nephropathy in adolescence: A prospective study. Nephrology (Carlton). 2017;22(9):678–83.

15. Lewis MJ, Botto M. Complement deficiencies in humans and animals: links to autoimmunity. AUTOIMMUNITY. 2006;39(5):367–78.

16. Walport MJ, Davies KA, Botto M. C1q and systemic lupus erythematosus. IMMUNOBIOLOGY. 1998;199(2):265–85.

17. Zhang XD, Cui Z, Zhang MF, Wang J, Zhang YM, Qu Z, et al. Clinical implications of pathological features of primary membranous nephropathy. BMC NEPHROL. 2018;19(1):215.

18. Francis JM, Beck LJ, Salant DJ. Membranous Nephropathy: A Journey From Bench to Bedside. AM J KIDNEY DIS. 2016;68(1):138–47.

19. Maifata SM, Hod R, Zakaria F, Abd GF. Primary Membranous Glomerulonephritis: The Role of Serum and Urine Biomarkers in Patient Management. Biomedicines. 2019;7(4).

20. Chen A, Frank R, Vento S, Crosby V, Chandra M, Gauthier B, et al. Idiopathic membranous nephropathy in pediatric patients: presentation, response to therapy, and long-term outcome. BMC NEPHROL. 2007;8:11.

Tables
Table 1 The parameters of PMN patients with or without C1q deposition.

| Parameters                          | C1q deposit (n=73) | No C1q deposit (n=73) | P     |
|-------------------------------------|--------------------|-----------------------|-------|
| Hyper tension, n(%)                | 22 (30.1)          | 26 (35.6)             | 0.481 |
| Nephrotic syndrome, n(%)            | 46 (63.0)          | 53 (72.6)             | 0.215 |
| Hematuria (×104/mL)                 | 30.00 (5.00—136.00)| 17.60 (4.50—93.85)    | 0.248 |
| Urinary protein (g/day)             | 2.83 (1.32—4.89)   | 2.45 (1.34—5.03)      | 0.809 |
| RBP (mg/L)                          | 0.30 (0.11—0.75)   | 0.29 (0.11—0.50)      | 0.691 |
| Urine NAG (U/g×cr)                  | 28.45 (15.65—45.20)| 25.70 (15.00—46.40)   | 0.720 |
| Serum albumin (g/L)                 | 23.69±6.93         | 22.54±5.68            | 0.968 |
| Cholesterol (mmol/L)                | 8.45±2.52          | 8.48±3.04             | 0.953 |
| Triglyceride (mmol/L)               | 2.15 (1.50—3.10)   | 2.16 (1.55—3.64)      | 0.531 |
| Serum creatinine (mg/dl)            | 0.62±0.17          | 0.62 (0.50—0.69)      | 0.533 |
| eGFR (mL/min/1.73m²)                | 148.13 (137.73—175.21) | 161.34 (141.07—193.28) | 0.154 |
| Serum urea nitrogen(mg/dl)          | 13.16±5.07         | 12.10 (8.91—15.96)    | 0.490 |
| Serum uric acid (umol/L)            | 362.97±98.30       | 375.14±108.78         | 0.432 |
| Serum - IgA (g/L)                   | 1.52 (1.03—2.01)   | 1.47±0.60             | 0.201 |
| Serum - IgG (g/L)                   | 5.18±2.69          | 4.41±2.28             | 0.053 |
| Serum - IgM (g/L)                   | 1.29 (0.91—1.78)   | 1.38 (1.03—1.86)      | 0.329 |
| Serum - C3 (g/L)                    | 1.12 (0.90—1.29)   | 1.11 (0.97—1.29)      | 0.670 |
| Serum - C4 (g/L)                    | 0.20 (0.15—0.25)   | 0.21±0.06             | 0.244 |
| Renal pathology, n(%)               |                    |                       |       |
| IgA deposit                         | 14 (19.2)          | 8 (11.0)              | 0.165 |
| IgM deposit                         | 14 (19.2)          | 13 (17.8)             | 0.831 |
| C3 deposit                          | 70 (95.9)          | 66 (90.4)             | 0.326 |
| C4 deposit                          | 25 (34.2)          | 4 (5.5)               | 0.000 |
| Churg's stages, n(%)                |                    |                       |       |
| MN-I                                | 18 (24.7)          | 16 (21.9)             | 0.522 |
| MN-II                               | 27 (37.0)          | 31 (42.5)             |       |
| MN-III                              | 26 (35.6)          | 19 (26.0)             |       |
| Immunosuppressive treatments, n(%)  | 60 (82.2)          | 56 (76.7)             | 0.413 |
| Treatment responses, n(%)           |                    |                       |       |
| Remission                           | 62 (84.9)          | 64 (87.7)             | 0.630 |
| Complete remission                  | 40 (54.8)          | 43 (58.9)             |       |
| Partial remission                   | 22 (30.1)          | 21 (28.8)             |       |
| No remission                        | 11 (15.1)          | 10 (13.7)             | 0.814 |
| Relapse, n(%)                       | 13 (17.8)          | 20 (27.4)             | 0.166 |
| Renal dysfunction, n(%)             | 4 (5.5)            | 8 (11.0)              | 0.366 |
| ESRD, n(%)                          | 3 (4.1)            | 5 (6.8)               | 0.716 |

RBP: retinol binding protein; NAG: N-acetyl-beta-D glucosaminidase; eGFR: estimate glomerular filtration rate;
### Table 2 The glomerular IgG subclass of PMN patients with and without C1q deposits

| Glomerular IgG subclass | C1q deposit (n=37) | No C1q deposit (n=42) | P     |
|------------------------|--------------------|-----------------------|-------|
| IgG1                   | 36(97.3%)          | 42(100.0%)            | 0.468 |
| IgG2                   | 33(89.2%)          | 37(88.1%)             | 1.000 |
| IgG3                   | 30(81.1%)          | 34(81.0%)             | 0.988 |
| IgG4                   | 35(94.6%)          | 42(100.0%)            | 0.216 |

### Table 3 The logistic regression analysis of the risk factors for no-remission of children with PMN.

| Parameter                   | OR (95%CI)        | P     |
|-----------------------------|-------------------|-------|
| Gender (male)               | 0.611(0.230—1.620) | 0.322 |
| Age (increased by 1 year)   | 1.019 (0.797—1.301) | 0.883 |
| Hypertension                | 1.656 (0.625—4.385) | 0.310 |
| Hypoalbuminemia             | 3.118 (0.826—11.771) | 0.093 |
| Proteinuria > 50mg/kg/day   | 1.615 (0.609—4.281) | 0.035 |
| eGFR                        | 0.998 (0.987—1.008) | 0.659 |
| C1q deposition              | 0.748 (0.287—1.951) | 0.553 |
Table 4 The Cox regression analysis of the risk factors for renal dysfunction in children with PMN

| Parameters            | Univariate analysis | Multivariate analysis |
|-----------------------|---------------------|-----------------------|
|                       | HR (95%CI)          | P         | HR (95%CI)          | P         |
| Gender (male)         | 6.749 (0.870—52.344) | 0.068 | 5.972 (0.757—47.129) | 0.090 |
| Age (increased by 1 year) | 1.229 (0.832—1.814) | 0.300 |
| Hypertension          | 1.309 (0.402—4.261)  | 0.655 |
| Hypoalbuminemia       | 5.971 (0.767—46.486) | 0.088 | 4.381 (0.561—34.194) | 0.159 |
| Proteinuria >50mg/kg/day | 2.016 (0.646—6.295)  | 0.227 |
| C1q deposition        | 0.428 (0.128—1.431)  | 0.168 |
| No remission          | 8.866 (2.347—33.495) | 0.001 | 9.064 (2.400—34.233) | 0.001 |

Figures
The Kaplan-Meier survival analysis compared the renal survival rates of ESKD between the patients with and without C1q deposition.
The Kaplan-Meier survival analysis compared the renal survival rates of ESKD or renal dysfunction between the patients with and without C1q deposition.